{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T14:18:36Z","timestamp":1775312316504,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"crossref","award":["021515"],"award-info":[{"award-number":["021515"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s00277-023-05209-2","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T09:03:01Z","timestamp":1681376581000},"page":"2909-2922","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of combined test dose and therapeutic drug monitoring strategy in exposure-directed busulfan"],"prefix":"10.1007","volume":"102","author":[{"given":"Tomoki","family":"Iemura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8959-6271","authenticated-orcid":false,"given":"Tadakazu","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Maeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Kitawaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junya","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazunori","family":"Imada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoyuki","family":"Anzai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuru","family":"Itoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoharu","family":"Takeoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Akasaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Yago","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihito","family":"Yonezawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyoshi","family":"Arima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiyuki","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaharu","family":"Nohgawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsumasa","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshinori","family":"Moriguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kouhei","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunori","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kana","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akifumi","family":"Takaori-Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,13]]},"reference":[{"issue":"13","key":"5209_CR1","doi-asserted-by":"publisher","first-page":"3569","DOI":"10.1182\/blood.V98.13.3569","volume":"98","author":"G Socie","year":"2001","unstructured":"Socie G, Clift RA, Blaise D et al (2001) Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood 98(13):3569\u20133574","journal-title":"Blood"},{"issue":"10","key":"5209_CR2","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/j.bbmt.2011.02.007","volume":"17","author":"G Alatrash","year":"2011","unstructured":"Alatrash G, de Lima M, Hamerschlak N et al (2011) Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life. Biol Blood Marrow Transplant 17(10):1490\u20131496","journal-title":"Biol Blood Marrow Transplant"},{"issue":"24","key":"5209_CR3","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1182\/blood-2013-08-519009","volume":"122","author":"C Bredeson","year":"2013","unstructured":"Bredeson C, LeRademacher J, Kato K et al (2013) Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation. Blood 122(24):3871\u20133878","journal-title":"Blood"},{"issue":"20","key":"5209_CR4","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.2174\/138161208785061382","volume":"14","author":"JA Russell","year":"2008","unstructured":"Russell JA, Kangarloo SB (2008) Therapeutic drug monitoring of busulfan in transplantation. Curr Pharm Des 14(20):1936\u20131949","journal-title":"Curr Pharm Des"},{"issue":"2","key":"5209_CR5","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.bbmt.2007.10.028","volume":"14","author":"M Geddes","year":"2008","unstructured":"Geddes M, Kangarloo SB, Naveed F et al (2008) High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen. Biol Blood Marrow Transplant 14(2):220\u2013228","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"5209_CR6","first-page":"1015","volume":"24","author":"M Czerwinski","year":"1996","unstructured":"Czerwinski M, Gibbs JP, Slattery JT (1996) Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos 24(9):1015\u20131019","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"5209_CR7","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.bbmt.2010.12.708","volume":"17","author":"SD Kim","year":"2011","unstructured":"Kim SD, Lee JH, Hur EH et al (2011) Influence of GST gene polymorphisms on the clearance of intravenous busulfan in adult patients undergoing hematopoietic cell transplantation. Biol Blood Marrow Transplant 17(8):1222\u20131230","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"5209_CR8","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1038\/bmt.2011.55","volume":"47","author":"MH ten Brink","year":"2012","unstructured":"ten Brink MH, Wessels JA, den Hartigh J et al (2012) Effect of genetic polymorphisms in genes encoding GST isoenzymes on BU pharmacokinetics in adult patients undergoing hematopoietic SCT. Bone Marrow Transplant 47(2):190\u2013195","journal-title":"Bone Marrow Transplant"},{"key":"5209_CR9","doi-asserted-by":"crossref","unstructured":"Michaud V, Tran M, Pronovost B et al (2019) Impact of GSTA1 polymorphisms on busulfan oral clearance in adult patients undergoing hematopoietic stem cell transplantation. Pharmaceutics 11(9):440","DOI":"10.3390\/pharmaceutics11090440"},{"issue":"2","key":"5209_CR10","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s00280-005-0029-0","volume":"57","author":"L Nguyen","year":"2006","unstructured":"Nguyen L, Leger F, Lennon S, Puozzo C (2006) Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. Cancer Chemother Pharmacol 57(2):191\u2013198","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"5209_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40262-020-00947-2","volume":"60","author":"R Lawson","year":"2021","unstructured":"Lawson R, Staatz CE, Fraser CJ, Hennig S (2021) Review of the pharmacokinetics and pharmacodynamics of intravenous busulfan in paediatric patients. Clin Pharmacokinet 60(1):17\u201351","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"5209_CR12","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1053\/bbmt.2002.v8.pm12374452","volume":"8","author":"BS Andersson","year":"2002","unstructured":"Andersson BS, Thall PF, Madden T et al (2002) Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 8(9):477\u2013485","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"5209_CR13","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/00007691-199810000-00017","volume":"20","author":"JT Slattery","year":"1998","unstructured":"Slattery JT, Risler LJ (1998) Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit 20(5):543\u2013549","journal-title":"Ther Drug Monit"},{"issue":"4 Suppl 4","key":"5209_CR14","first-page":"18","volume":"20","author":"LB Grochow","year":"1993","unstructured":"Grochow LB (1993) Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 20(4 Suppl 4):18\u201325 (quiz 26)","journal-title":"Semin Oncol"},{"issue":"4","key":"5209_CR15","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/bmt.2016.322","volume":"52","author":"BS Andersson","year":"2017","unstructured":"Andersson BS, Thall PF, Valdez BC et al (2017) Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML\/MDS patients. Bone Marrow Transplant 52(4):580\u2013587","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"5209_CR16","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.bbmt.2016.07.013","volume":"22","author":"J Palmer","year":"2016","unstructured":"Palmer J, McCune JS, Perales MA et al (2016) Personalizing busulfan-based conditioning: considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. Biol Blood Marrow Transplant 22(11):1915\u20131925","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"5209_CR17","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1515\/CCLM.2004.095","volume":"42","author":"K Matsuno","year":"2004","unstructured":"Matsuno K, Kubota T, Matsukura Y, Ishikawa H, Iga T (2004) Genetic analysis of glutathione S-transferase A1 and T1 polymorphisms in a Japanese population. Clin Chem Lab Med 42(5):560\u2013562","journal-title":"Clin Chem Lab Med"},{"issue":"3","key":"5209_CR18","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1002\/jcph.1049","volume":"58","author":"KM Brooks","year":"2018","unstructured":"Brooks KM, Jarosinski P, Hughes T et al (2018) Test dose pharmacokinetics in pediatric patients receiving once-daily IV busulfan conditioning for hematopoietic stem cell transplant: a reliable approach? J Clin Pharmacol 58(3):332\u2013339","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"5209_CR19","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1111\/bcp.14256","volume":"86","author":"JB Langenhorst","year":"2020","unstructured":"Langenhorst JB, Boss J, van Kesteren C et al (2020) A semi-mechanistic model based on glutathione depletion to describe intra-individual reduction in busulfan clearance. Br J Clin Pharmacol 86(8):1499\u20131509","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"5209_CR20","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1016\/j.bbmt.2016.07.008","volume":"22","author":"K Matsumoto","year":"2016","unstructured":"Matsumoto K, Uchida N, Sakurai A, Taniguchi S, Morita K (2016) Clinical application of the dried blood spot method in the measurement of blood busulfan concentration. Biol Blood Marrow Transplant 22(11):1968\u20131973","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"5209_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12185-015-1894-x","volume":"103","author":"Y Atsuta","year":"2016","unstructured":"Atsuta Y (2016) Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol 103(1):3\u201310","journal-title":"Int J Hematol"},{"issue":"3","key":"5209_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1053\/bbmt.2002.v8.pm11939604","volume":"8","author":"BS Andersson","year":"2002","unstructured":"Andersson BS, Kashyap A, Gian V et al (2002) Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation: a phase II study. Biol Blood Marrow Transplant 8(3):145\u2013154","journal-title":"Biol Blood Marrow Transplant"},{"key":"5209_CR23","first-page":"477","volume":"16","author":"AJ Weiss","year":"1962","unstructured":"Weiss AJ, Jackson LG, Carabasi RA, Mancall EL, White JC (1962) A phase I study of dimethylacetamide. Cancer Chemother Rep 16:477\u2013485","journal-title":"Cancer Chemother Rep"},{"issue":"12","key":"5209_CR24","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/j.bbmt.2012.06.010","volume":"18","author":"P Kebriaei","year":"2012","unstructured":"Kebriaei P, Basset R, Ledesma C et al (2012) Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 18(12):1819\u20131826","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"5209_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/bmt.2012.114","volume":"48","author":"P Kebriaei","year":"2013","unstructured":"Kebriaei P, Madden T, Wang X et al (2013) Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL. Bone Marrow Transplant 48(1):26\u201331","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"5209_CR26","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1007\/s12185-017-2187-3","volume":"105","author":"M Takagi","year":"2017","unstructured":"Takagi M, Ishiwata Y, Aoki Y et al (2017) HLA haploidentical hematopoietic cell transplantation using clofarabine and busulfan for refractory pediatric hematological malignancy. Int J Hematol 105(5):686\u2013691","journal-title":"Int J Hematol"},{"issue":"6 Suppl","key":"5209_CR27","doi-asserted-by":"publisher","first-page":"1552S","DOI":"10.1093\/ajcn\/53.6.1552S","volume":"53","author":"JD Curb","year":"1991","unstructured":"Curb JD, Marcus EB (1991) Body fat and obesity in Japanese Americans. Am J Clin Nutr 53(6 Suppl):1552S-1555S","journal-title":"Am J Clin Nutr"},{"issue":"10","key":"5209_CR28","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1002\/cncr.33383","volume":"127","author":"B Oran","year":"2021","unstructured":"Oran B, Saliba RM, Mehta RS et al (2021) Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer 127(10):1598\u20131605","journal-title":"Cancer"},{"issue":"11","key":"5209_CR29","doi-asserted-by":"publisher","first-page":"e526","DOI":"10.1016\/S2352-3026(16)30114-4","volume":"3","author":"IH Bartelink","year":"2016","unstructured":"Bartelink IH, Lalmohamed A, van Reij EML et al (2016) Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol 3(11):e526\u2013e536","journal-title":"Lancet Haematol"},{"issue":"5","key":"5209_CR30","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/hon.2789","volume":"38","author":"I Esteves","year":"2020","unstructured":"Esteves I, Santos FPS, Ribeiro AAF et al (2020) Targeted-dose of busulfan: higher risk of sinusoidal obstructive syndrome observed with systemic exposure dose above 5000 microMolmin. A historically controlled clinical trial. Hematol Oncol 38(5):773\u2013781","journal-title":"Hematol Oncol"},{"key":"5209_CR31","doi-asserted-by":"publisher","first-page":"8690416","DOI":"10.1155\/2017\/8690416","volume":"2017","author":"S Farhan","year":"2017","unstructured":"Farhan S, Bazydlo M, Neme K, Mukulandric N, Peres E, Janakiraman N (2017) Chimerism in myeloid malignancies following stem cell transplantation using FluBu4 with and without busulfan pharmacokinetics versus BuCy. Adv Hematol 2017:8690416","journal-title":"Adv Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05209-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05209-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05209-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T10:03:28Z","timestamp":1694253808000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05209-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,13]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["5209"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05209-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,13]]},"assertion":[{"value":"11 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Our protocol complied with the Declaration of Helsinki and was approved by the institutional review board of each participating institution and the central review board of Kyoto University Hospital. Written informed consent was obtained from each patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}